ArticleArchives of osteoporosis2025
Early transition from short-term romosozumab to antiresorptive therapies: analysis of 26 cases.
Article in Archives of osteoporosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial.The lancet. Diabetes & endocrinology · 2026Trial
- Revisiting the activate depress free and repeat (ADFR) paradigm: Clinical use of cyclic romosozumab.Archives of osteoporosis · 2026Article
- Romosozumab in severe postmenopausal osteoporosis-real-world data from 192 women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Romosozumab super-responders in clinical practice: insights from a large Italian multicenter cohort of women with severe postmenopausal osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This multicentre, retrospective case series analysed bone mineral density (BMD) changes in 26 patients who switched early from romosozumab (3-10 months) to antiresorptives. BMD gains over 12 months were similar to those in patients (n = 99) completing the full 12-month course.
backgroundRomosozumab is typically administered for a duration of 12 months before transitioning to antiresorptive therapies. This study analysed the bone mineral density (BMD) changes of patients who were prematurely switched to an antiresorptive regimen.
methodsThis multicentre, retrospective case series investigated the BMD response to romosozumab administered for 3 to 10 months, followed by subsequent antiresorptive therapy, across four bone centres in Switzerland. BMD measurements at the lumbar spine, total hip and femoral neck were conducted at the initiation of romosozumab and again 12 months later. The study compared the BMD changes in patients who received short-term romosozumab with those in a cohort of patients who completed the full 12-month course.
resultsTwenty-six patients (25 postmenopausal women and one man, median age 73 years [interquartile range: 65, 81]) were enrolled from February 2022 to December 2024. They received a median of six romosozumab injections (range: 3 to 10) and were prematurely switched to antiresorptives (14 to denosumab, 11 to zoledronate and one to alendronate) due to possible side effects or adverse events. Over 12 months, BMD increased by 13.5% [8.6, 16.6] at the lumbar spine, 2.9% [0.3, 7.3] at the total hip and 3.2% [0.4, 7.8] at the femoral neck, without significant differences compared with the cohort of 99 patients who received 12 months of romosozumab therapy. In both the short- and full-duration romosozumab treatment groups, significantly lower BMD responses were observed in patients who were pretreated with antiresorptives compared with those who were treatment naïve.
conclusionIn patients who underwent an early switch from romosozumab to antiresorptive therapy, BMD responses during the first year were similar to those in patients who completed the full 12-month romosozumab treatment. However, the subsequent changes in BMD, when all patients are receiving antiresorptive therapy, remain to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.